Nurse Practitioner · Toledo, OH
NPI
1124177514
Since 2007
Specialty
Nurse Practitioner
Code 363L00000X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
2130 W Central Ave Ste 201
Toledo, OH, 43606
Phone (419) 291-3900
Groups this clinician bills Medicare through
Medicare paid, 2024
$20K
221 services
Medicare patients, 2024
144
Average age 76
Drug cost, 2024
$1.3M
2,545 prescriptions
Company payments, 2025
$894
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mary E Scott was code 99215 (office e&m - established), 136 times for 106 patients. In total Mary E Scott billed 221 services in 10 codes, and Medicare paid $20K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-12-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 136 | 106 | $110.31 | $15K |
| 99214 Office E&M - Established | Office | 39 | 36 | $75.34 | $2,938 |
| 99213 Office E&M - Established | Office | 11 | 11 | $49.68 | $546 |
By year: 2022 $13K for 168 services; 2023 $18K for 192 services; 2024 $20K for 221 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mary E Scott prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 405 prescriptions and refills. In total Mary E Scott wrote 2,545 Medicare prescriptions that cost $1.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 405 | 928 | 118 | $17K |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 290 | 736 | 99 | $27K |
| Rasagiline Mesylate Generic | 207 | 556 | 57 | $71K |
| Rivastigmine Generic | 126 | 244 | 38 | $29K |
| Rytary Carbidopa/Levodopa | 123 | 231 | 28 | $151K |
| Venlafaxine Hcl Er Venlafaxine Hcl | 100 | 259 | 23 | $1,725 |
| Amantadine Amantadine Hcl | 96 | 222 | 27 | $6,781 |
| Nuplazid Pimavanserin Tartrate | 86 | 118 | 12 | $663K |
| Gabapentin Generic | 73 | 125 | 18 | $1,276 |
| Donepezil Hcl Generic | 69 | 133 | 20 | $760 |
| Quetiapine Fumarate Generic | 68 | 133 | 19 | $1,585 |
| Clonazepam Generic | 63 | 109 | 22 | $877 |
| Ongentys Opicapone | 55 | 79 | 12 | $50K |
| Memantine Hcl Generic | 49 | 82 | 11 | $2,162 |
| Mirtazapine Generic | 48 | 96 | 16 | $1,595 |
Brand drugs: 453 claims; generic drugs: 2,092 claims; opioid claims: 12.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mary E Scott $894 ($894 in general payments such as food, travel and fees) from 15 companies. The largest payer was Abbvie Inc. with $231.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 8 | $231 |
| Teva Pharmaceuticals USA, Inc. TEVA | 2 | $196 |
| Amneal Pharmaceuticals LLC AMRX | 2 | $141 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $86.7 |
| SK Life Science, Inc. | 2 | $34.38 |
| Merz Pharmaceuticals, LLC | 2 | $31.97 |
| ACADIA Pharmaceuticals Inc ACAD | 2 | $30.33 |
| Genentech USA, Inc. ROG.SW | 1 | $25.12 |
| TG Therapeutics, Inc. TGTX | 1 | $22.93 |
| UCB, Inc. UCB.BR | 1 | $18.18 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.